Jose Novo Matos

Jose Novo Matos

Auto-generated profile, based on publicly available information

Jose Novo Matos

Department of Veterinary Medicine, University of Cambridge , Madingley Road, Cambridge CB3 0ES

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
JMJ. Novo Matos
J. Novo Matos
NPN. Pereira
N. Pereira
TGT. Glaus
T. Glaus
LWL. Wilkie
L. Wilkie
KBK. Borgeat
K. Borgeat
VFV. Luis Fuentes
V. Luis Fuentes
Background Cats with hypertrophic cardiomyopathy (HCM) and congestive heart failure (CHF) can have resolution of both left ventricular hypertrophy and CHF. Objectives To describe the clinical characteristics of cats with transient myocardial thickening (TMT) and CHF compared with a control population of cats without resolution of HCM. Animals A total of 21 cats with TMT, 21 cats with HCM. Methods Retrospective study. Clinical records at 4 veterinary centers were searched for TMT cases and a control group of cats with HCM and CHF. TMT was defined as initial maximal left ventricular wall thickness (LVWT) ≥6 mm with left-sided CHF, with subsequent resolution of CHF, reduction in left atrium/aorta (LA/Ao), and LVWT<5.5 mm. HCM was defined as persistent LVWT ≥6 mm. Results Cats with TMT were younger (2 [0.4–11.4] years) than cats with HCM (8 [1.6–14] years) (P < 0.0001), and antecedent events were more common (15/21 versus 6/21, respectively) (P = 0.01). In cats with TMT, LVWT normalized from 6.8 [6.0–9.7] mm to 4.8 [2.8–5.3] mm and LA/Ao decreased from 1.8 [1.6–2.3] to 1.45 [1.2–1.7] after a mean interval of 3.3 (95% CI: 1.8–4.7) months. CHF recurred in 1 of 21 TMT and 15 of 21 cats with HCM. Cardiac treatment was discontinued in 20 of 21 cats with TMT and 0 of 21 HCM cats. All cats with TMT survived, whereas 8 of 19 cats with HCM died during the study period. Conclusions and Clinical Importance TMT occurs in younger cats, and antecedent events are common. The prognosis is better in cats with CHF associated with TMT than HCM.

31 October 2022 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
JMJose Novo Matos
Jose Novo Matos
JPJessie Rose Payne
Jessie Rose Payne
JSJoonbum Seo
Joonbum Seo
VFVirginia Luis Fuentes
Virginia Luis Fuentes
Background: The natural history of hypertrophic cardiomyopathy (HCM) in cats has been mainly studied in cats referred for suspected heart disease, which can skew the results towards cats with clinical signs. Few data are available on factors associated with development of HCM in cats. Hypotheses: (1) Clinical variables can predict which cats will develop HCM; (2) HCM in cats not referred for suspected heart disease is associated with a low rate of cardiovascular events. Animals: One hundred seven cats from rehoming centers without a history of clinical signs of cardiac or systemic disease at the time of adoption. Methods: Prospective longitudinal study. After rehoming, shelter cats were reexamined for serial echocardiograms. Cox regression analysis was used to identify predictors of development of HCM in cats that were normal at baseline. Adverse cardiovascular events including heart failure, thromboembolism, or sudden death were recorded. Results: Cats were monitored for a median of 5.6 [1.2-9.2] years. At baseline, 68/107 cats were normal, 18/107 were equivocal and 21/107 had HCM. Nineteen cats developed HCM during the study period. The factors at baseline associated with increased hazard of developing HCM were lower left atrial fractional shortening, higher left ventricular fractional shortening, and higher body weight. Cardiovascular events were observed in 21% of cats with HCM. Conclusions and Clinical Importance: Cardiovascular events were common in cats with HCM from a rehoming center study sample. Lower left atrial systolic function appears to precede overt HCM.

19 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JMJose Novo Matos
Jose Novo Matos
PGPatricia Garcia-Canadilla
Patricia Garcia-Canadilla
ISIan C. Simcock
Ian C. Simcock
JHJ. Ciaran Hutchinson
J. Ciaran Hutchinson
MDMelanie Dobromylskyj
Melanie Dobromylskyj
VFVirginia Luis Fuentes
Virginia Luis Fuentes
Micro-computed tomography (micro-CT) is a high-resolution imaging modality that provides accurate tissue characterization. Hypertrophic cardiomyopathy (HCM) occurs as a spontaneous disease in cats, and is characterized by myocardial hypertrophy, disarray and fibrosis, as in humans. While hypertrophy/mass (LVM) can be objectively measured, fibrosis and myocyte disarray are difficult to assess. We evaluated the accuracy of micro-CT for detection and quantification of myocardial disarray and fibrosis by direct comparison with histopathology. 29 cat hearts (12 normal and 17 HCM hearts) underwent micro-CT and pathologic examination. Myocyte orientation was assessed using structure tensor analysis by determination of helical angle (HA), fractional anisotropy (FA) and myocardial disarray index (MDI). Fibrosis was segmented and quantified based on comparison of gray-scale values in normal and fibrotic myocardium. LVM was obtained by determining myocardial volume. Myocardial segments with low FA, low MDI and disruption of normal HA transmural profile on micro-CT were associated with myocardial disarray on histopathology. FA was consistently lower in HCM than normal hearts. Assessment of fibrosis on micro-CT closely matched the histopathologic evaluation. LVM determined by micro-CT was higher in HCM than normal hearts. Micro-CT can be used to detect and quantify myocardial disarray and fibrosis and determine myocardial mass in HCM.

21 August 2020 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
JSJoonbum Seo
Joonbum Seo
JPJessie Rosie Payne
Jessie Rosie Payne
JMJose Novo Matos
Jose Novo Matos
WFWesley Wynne Fong
Wesley Wynne Fong
DCDavid J. Connolly
David J. Connolly
VFVirginia Luis Fuentes
Virginia Luis Fuentes
Background N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and cardiac troponin‐I (cTnI) are biomarkers commonly evaluated in cats with suspected heart disease. Many cats with hypertrophic cardiomyopathy (HCM) have systolic anterior motion of the mitral valve (SAM), but its influence on circulating NT‐proBNP or cTnI concentrations is currently unknown. Hypothesis/Objectives Cats with HCM and SAM (HCMSAM+) have higher NT‐proBNP and cTnI concentrations than do cats with HCM but without SAM (HCMSAM−). Animals One hundred forty cats with HCM: 70 with SAM and 70 without SAM. Methods Retrospective case‐to‐case study. Cats were recruited if diagnosed with HCM by echocardiography and results were available for NT‐proBNP or cTnI concentrations or both. Cats with SAM were matched to those without SAM for clinical presentation, left atrial (LA) size and left ventricular (LV) fractional shortening. Results A total of 119 NT‐proBNP and 123 cTnI results were available. The HCMSAM+ cats had higher median concentrations than did HCMSAM− cats for NT‐proBNP (729 pmoL/L; interquartile range [IQR], 275‐1467 versus 65 pmoL/L; IQR, 25‐271; P < .001) and cTnI (0.27 ng/mL; IQR, 0.10‐0.81 versus 0.07 ng/mL; IQR, 0.01‐0.43; P = .002). In general linear models for both NT‐proBNP and cTnI, the independent explanatory variables were SAM, congestive heart failure, maximal LV wall thickness, and LA size. Conclusions and Clinical Importance For cats with HCM and equivalent LA size and LV systolic function, those with SAM had higher NT‐proBNP and cTnI concentrations than did those without SAM. Presence of SAM should be considered when interpreting biomarker concentrations in cats with HCM.

1 December 2017 in Journal of Veterinary Cardiology
Verified
Journal Article
Closed access
DDDave Dickson
Dave Dickson
DCDomenico Caivano
Domenico Caivano
JMJose Novo Matos
Jose Novo Matos
NSNuala Summerfield
Nuala Summerfield
MRMark Rishniw
Mark Rishniw

1 May 2022 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
KSKarsten E. Schober
Karsten E. Schober
PFPhillip R. Fox
Phillip R. Fox
JAJonathan Abbott
Jonathan Abbott
ECEtienne Côté
Etienne Côté
VFVirginia Luis Fuentes
Virginia Luis Fuentes
JRJohn E. Rush
John E. Rush
Background: There is a lack of clinical data on hypertrophic cardiomyopathy (HCM) in dogs. Hypothesis/Objectives: To investigate signalment, clinical signs, diagnostic findings, and survival in dogs with HCM. Animals: Sixty-eight client-owned dogs. Methods: Retrospective multicenter study. Medical records were searched between 2003 and 2015. The diagnosis of left ventricular (LV) hypertrophy was made by echocardiographic examination. Results: Three hundred and forty-five dogs with LV hypertrophy were identified, of which 277 were excluded. The remaining 68 dogs were 0.3 to 14 years old and predominantly <10 kg (85%), and without a sex predilection. Twenty-four % were Shih Tzu and 24% terrier breeds. Most (80%) had a systolic heart murmur. Owner-determined exercise intolerance (37%) and syncope (18%) were most commonly reported signs. The majority (84%) of dogs had symmetrical LV hypertrophy, whereas asymmetrical septal and LV free wall hypertrophy was observed in 9% and 6% of dogs, respectively. Isolated basal interventricular septal hypertrophy was not observed. Commonly recorded were systolic anterior motion of the mitral valve (60%) and LV diastolic dysfunction (89% of dogs where diastolic function was evaluated). Six dogs died unexpectedly, and 3 developed congestive heart failure. Known survival times were between 1 day and 114 months after diagnosis. Conclusions and Clinical Importance: Hypertrophic cardiomyopathy in dogs should be considered as a differential diagnosis if LV hypertrophy is identified. Small breed dogs are overrepresented, and it is uncommon for dogs with HCM to develop CHF although sudden death can occur.